

Resonance Health Limited

ABN: 96 006 762 492

CHANGE OF ASX CODES FOR RESONANCE HEALTH LIMITED (formerly GEO2 Limited)

15 December 2003

Resonance Health Limited is please to advise all shareholders and interested parties that as of 15 December 2003, the Company's securities will commence trading under new ASX codes as follows:

Resonance Health Limited:

| | <u>New Code</u> | <u>Old Code</u> |
|------------------------------------|-----------------|-----------------|
| Ordinary Shares | RHT | GEL |
| Options – 15 cent, 15/01/07 | RHTOA | GELOA |

This now completes the transformation of GEO2 Limited into Resonance Health Limited.

ABOUT THE COMPANY

Resonance Health Limited controls 51% of the voting rights of Inner Vision Biometrics Pty Ltd (IVB) and is earning 51% of the equity of IVB via the injection of further capital. IVB is the 100% owner of **FerriScan**.

FerriScan is a novel, non-invasive liver diagnostic test with global applications. The test accurately measures the iron content of a patient's liver to assist clinicians in the detection and treatment of iron overload disorders such as Thalassemia and Hereditary Haemochromatosis. It is intended that the FerriScan test will replace the need for liver biopsy and become a valuable adjunct to gene testing for iron overload diseases. Liver biopsy is an unpleasant, invasive procedure requiring liver tissue to be extracted from the patient by needle. Other even broader applications for FerriScan linked to Hepatitis and Fibrosis of the Liver are presently being pursued.

For more information please contact:

Tony Fitzgerald
Managing Director
Resonance Health Limited
08 9389 5933
tfitzgerald@resonancehealth.com

Evan Cross
Company Secretary
Resonance Health Limited
08 9389 5933
ecross@resonancehealth.com

Or visit Resonance's website on www.resonancehealth.com, or FerriScan's website on www.ferriscan.com